Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study reveals hidden toll of chemo: taste loss and muscle wasting in gynecologic cancer patients

NCT ID NCT07154966

Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study followed 102 women with ovarian, fallopian tube, or endometrial cancer through six cycles of standard chemotherapy (carboplatin and paclitaxel). Researchers measured taste changes, muscle loss, and nutritional decline at the start, halfway, and end of treatment. The goal was to better understand these side effects so doctors can offer better support in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

102 people

The number who actually took part.

Started

Mar 2024

Finished

Jul 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult female patients (≥18 years) with histologically confirmed non-metastatic ovarian, fallopian tube, or endometrial cancer who are receiving adjuvant or neoadjuvant carboplatin-paclitaxel chemotherapy at Ankara Etlik City Hospital. A total of 102 patients will be enrolled. Participants must have completed six cycles of standard chemotherapy and have available CT imaging at baseline, after the third cycle, and after the sixth cycle to allow prospective evaluation of taste alterations, nutritional status, and sarcopenia.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of non-metastatic ovarian, fallopian tube, or endometrial cancer * Planned to receive adjuvant or neoadjuvant carboplatin-paclitaxel regimen (carboplatin AUC 5 + paclitaxel 175-200 mg/m² every 21 days) * No prior chemotherapy * Age ≥ 18 years, female * Completion of 6 cycles of carboplatin-paclitaxel treatment * Availability of CT imaging at baseline, after third cycle, and after sixth cycle * Ability to provide written informed consent Exclusion Criteria: * Metastatic disease or palliative treatment setting * Treatment with regimens other than carboplatin-paclitaxel or weekly protocols * Prior systemic therapy (e.g., immunotherapy, targeted therapy) Initial treatment discontinuation due to progression, toxicity, or patient preference * Missing CT imaging at required timepoints * Pregnancy or breastfeeding * Cognitive impairment or inability to provide informed consent * Severe comorbid conditions (e.g., uncontrolled cardiac disease, end-stage renal failure, advanced liver failure) * Inability to comply with study assessments or follow-up visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer-associated malnutrition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dysgeusia endometrial cancer endometrium neoplasm fallopian tube cancer fallopian tube neoplasm Malnutrition ovarian cancer Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer-associated malnutrition Cancer-associated sarcopeni Chemotherapy-induced taste alteration Endometrial cancer Fallopian tube cancers Ovarian cancer (OVCA)

Contacts and locations

Locations

  • Ankara Etlik City Hospital

    Ankara, Yenimahalle, 06210, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.